[ Back to EurekAlert! ] Public release date: 27-Sep-2012
[ | E-mail Share Share ]

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Treating hepatitis C infection in prison is good public policy

Incarcerated patients with chronic hepatitis C virus (HCV) infection are just as likely to respond to treatment for the disease as patients in the community, according to findings published in the October issue of Hepatology, a peer-reviewed journal of the American Association for the Study of Liver Diseases. The study from the University of Wisconsin School of Medicine and Public Health (SMPH) in Madison found that HCV patients in prison were just as likely to achieve a sustained viral response (SVR) as non-incarcerated patients.

Medical evidence reports that chronic HCV is the leading cause of end-stage liver disease (ESLD) and liver disease mortality in the U.S. Further studies have shown the risk of developing cirrhosis due to chronic HCV ranges between 5 and 25 percent over a 25 to 30 year period. Consequences caused by chronic HCV are major public health concerns within the U.S. prison system, with research conducted by the Centers for Disease Control and Prevention (CDC) estimating up to 31 percent of U.S. inmates have chronic HCV, compared to just two percent of the general population in this country.

"Given that a history of intravenous drug use is more frequent among inmates, there is a higher prevalence of HCV infection in the prison population," explains lead author Dr. Michael Lucey, Chief of the Division of Gastroenterology and Hepatology at the SMPH. "HCV treatment during incarceration provides an opportunity to make a significant improvement to public health."

Incarcerated and non-incarcerated patients with HCV who were seen at the University of Wisconsin Hepatology or Infectious Diseases Clinic between January 2002 and December 2007, were evaluated for antiviral therapy. Researchers identified 521 general-population patients and 388 from the prison population who were evaluated for HCV therapy.

Results show that 61 percent of non-incarcerated and 60 percent of incarcerated patients received treatment with pegylated interferon and ribavirin. Those from the prison population were more likely to be African-American males with a history of alcohol or intravenous drug use. The team reported that SVR was achieved in 43 percent of prisoners compared to 38 percent of patients in the general-population group.

"Our findings highlight the effectiveness of antiviral therapy in HCV-infected prisoners, and show that it is as successful as treatment for HCV patients in the general population," concludes Dr. Lucey. "With previous studies citing poor results of HCV treatment in high-risk groups on an outpatient basis, a correctional setting may be an optimal setting for treatment that will help curb the hepatitis C public health crisis."

###

This research was funded by the American Cancer Society Research Scholar Grant, the National Institutes of Health (NIH) Clinical and Translational Science Award, and by the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources at NIH.

This study is published in Hepatology. Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com.

Full citation: "Comparison of Hepatitis C Virus Treatment Between Incarcerated and Community Patients." John P. Rice, David Burnett, Helena Tsotsis, Mary J. Lindstrom, Daniel D. Cornett, Patricia Voermans, Jill Sawyer, Rob Striker and Michael R. Lucey. Hepatology; (DOI: 10.1002/hep.25770; Print Issue Date: October, 2012.

URL: http://onlinelibrary.wiley.com/doi/10.1002/hep.25770/abstract.

Author Contact: To arrange an interview with Dr. Michael Lucey, please contact Mike Klawitter with University of Wisconsin Hospital and Clinics Public Affairs in Madison, WI at mklawitter@uwhealth.org or at +1 608-265-8199.

About the Journal

Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.

About Wiley

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace.

Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.